KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Cash & Current Investments (2018 - 2025)

Adaptive Biotechnologies' Cash & Current Investments history spans 8 years, with the latest figure at $227.0 million for Q4 2025.

  • For Q4 2025, Cash & Current Investments rose 2.11% year-over-year to $227.0 million; the TTM value through Dec 2025 reached $227.0 million, up 2.11%, while the annual FY2025 figure was $227.0 million, 2.11% up from the prior year.
  • Cash & Current Investments for Q4 2025 was $227.0 million at Adaptive Biotechnologies, up from $212.8 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $714.3 million in Q1 2021 and bottomed at $193.4 million in Q1 2025.
  • The 5-year median for Cash & Current Investments is $358.3 million (2021), against an average of $365.4 million.
  • The largest annual shift saw Cash & Current Investments crashed 50.3% in 2021 before it soared 41.11% in 2022.
  • A 5-year view of Cash & Current Investments shows it stood at $353.1 million in 2021, then skyrocketed by 41.11% to $498.2 million in 2022, then plummeted by 30.47% to $346.4 million in 2023, then tumbled by 35.83% to $222.3 million in 2024, then rose by 2.11% to $227.0 million in 2025.
  • Per Business Quant, the three most recent readings for ADPT's Cash & Current Investments are $227.0 million (Q4 2025), $212.8 million (Q3 2025), and $197.9 million (Q2 2025).